ArticleExperimental physiology2026
Effects of chemical myosin II cross-bridge inhibitors on eccentric force production in skinned muscle fibres.
Article in Experimental physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effects of chemical myosin II cross-bridge inhibitors on eccentric force production in skinned muscle fibres.Experimental physiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Eccentric muscle contractions are essential for locomotion and daily activities. Force during these contractions depends on both cross-bridge (XB) and non-cross-bridge (non-XB) elements, including titin, with contributions varying by fibre type and contraction velocity. Despite their importance, mechanisms of force generation during prolonged stretches remain unclear. Chemical XB inhibitors are commonly used to separate XB and non-XB contributions, but their effects have not been systematically compared under identical conditions. We measured eccentric force in single permeabilised fibres from fast-twitch rat extensor digitorum longus (EDL) and slow-twitch soleus (SOL) muscles. Fibres were treated with blebbistatin (Bleb), 2,3-butanedione monoxime (BDM), or N-benzyl-p-toluene sulphonamide (BTS) and stretched from 0.85 to 1.3 times optimal length at three velocities (0.01, 0.1 and 1.0 maximal contraction velocity). XB inhibition produced fibre-type-dependent effects on early- and late-stretch force (slope
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.